Datasheet

IDH2 Antibody
CATALOG NUMBER: 5821

Availability: In stock

$0.00
Product Price Options

* Required Fields

$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse, Rat
HOMOLOGY:Predicted species reactivity based on immunogen sequence: Bovine: (88%)
TESTED APPLICATIONS:ELISA, IF, IHC-P, WB
APPLICATIONS:IDH2 antibody can be used for detection of IDH2 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1301 - Human Heart Tissue Lysate
IMMUNOGEN:IDH2 antibody was raised against a 17 amino acid synthetic peptide near the amino terminus of human IDH2.

The immunogen is located within the first 50 amino acids of IDH2.
HOST SPECIES:Rabbit

Properties

PURIFICATION:IDH2 Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:IDH2 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:IDH2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:IDH2 Antibody: IDH, IDP, IDHM, IDPM, ICD-M, D2HGA2, mNADP-IDHICD-M, IDH
ACCESSION NO.:NP_002159
PROTEIN GI NO.:28178832
OFFICIAL SYMBOL:IDH2
GENE ID:3418

Background

BACKGROUND:IDH2 Antibody: Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD(+) as the electron acceptor and the other NADP(+). Two NADP(+)-dependent isocitrate dehydrogenases have been found as homodimer: IDH1 is predominantly cytosolic and peroxisomal and IDH2 is mitochondrial. Both IDH1 and IDH2 play significant roles in the tricarboxylic acid cycle (TCA), and defects in IDH1 as well as IDH2 have been implicated in the development of glioma as well as other malignancies.
REFERENCES: 1) Geisbrecht BV and Gould SJ. The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J. Biol. Chem.1999; 274:30527-33.
2) Przybyla-Zawislak B, Gadde DM, Ducharme K, et al. Genetic and biochemical interactions involving tricarboxylic acid cycle (TCA) function using a collection of mutants defective in all TCA cycle genes. Genetics1999; 152:153-66.
3) Dang L, White DW, and Gross S. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature2009; 462:739-44.
4) Tan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med.2009; 360:765-73.

For Research Use Only